A major cause of pain and disability, rheumatoid arthritis (RA) is also potentially the most treatable form of chronic arthritis. Researchers, doctors, and patients agree that a group of drugs called disease-modifying antirheumatic drugs (DMARDs) can effectively reduce joint pain and stiffness. Yet, even when prescribed early and aggressively, DMARDs alone do not guarantee the desired outcome: the rapid and prolonged suppression of inflammation needed to induce remission.
Fortunately, there is new hope for treating RA early and experiencing long-lasting gains. Biologic agents that target tumor necrosis factor (TNF)-alpha – a protein known for provoking inflammation – have been successfully used to curtail the activity of rheumatoid arthritis among other chronic inflammatory conditions. Recently, a team of researchers in the United Kingdom set out to test the effectiveness of anti-TNF-alpha therapy on a small sample of patients with very early, poor-prognosis, previously untreated RA. The promising results and practical treatment implications of their pilot study are featured in the January 2005 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis).
Based at Leeds General Infirmary, the research team recruited twenty patients with a diagnosis of RA meeting the American College of Rheumatology's criteria. On average, the patients had complained of disease symptoms for six months. None had ever been prescribed DMARDs or steroids. At the study's onset, the patients were randomly divided into two treatment groups. One group received a standard dosage of a TNF-alpha inhibitor, infliximab (also known by the commercial name Remicade), while the other group received the a placebo. Patients in both groups also began a course of escalating DMARD therapy with methotrexate. DMARDs are drugs that improve the signs and symptoms of RA and reduce damage as shown by joint X-rays
All twenty RA patients adhered to their assigned treatment for a full year. To closely monitor the impact of anti-TFN-alpha therapy on synovitis, the inflammation of the membrane lining the joints, as well as bone erosions, every patient underwent magnetic resonance imaging (MRI) scans of the hand at baseline, at four weeks, and then at eight-week intervals until 54 weeks. The MRI scans were repeated a final time at 104 weeks – one year after the patients stopped taking infliximab.
At its one-year culmination, the study achieved its primary goal for RA patients given the advantage of early anti-TNF-alpha therapy: disease remission to avert joint damage. At 14 weeks, according to the MRI findings, patients taking infliximab combined with methotrexate showed a significant reduction in levels of synovitis compared to their baseline scores and to their counterparts. At 24 weeks, the infliximab group had significantly fewer new telltale signs of joint erosions than the placebo group. Throughout the course of the study, up to week 104, remission rates were greater among those patients prescribed infliximab plus methotrexate. 7 out of 10 of the patients had met the ACR response criteria for remission, compared with 2 out of 10 patients in the placebo plus methotrexate group.
One year after withdrawing from anti-TNF-alpha therapy, the patients in this group continued to experience therapeutic benefits. These patients scored significantly higher on measures of function and quality of life than the patients who had been treated with conventional DMARDs alone. "This appears to emphasize the importance of not only adequate disease suppression over time, but also of rapid disease suppression for optimal improvement in these outcomes," notes the study's author, Mark A. Quinn. "Rapid control of disease activity may prevent patients from entering the 'sick role' and may avoid the socioeconomic disadvantages associated with chronic illness, which extend beyond the anti-inflammatory nature of the therapy."
Despite the small sample of patients, this study has important implications for the most effective, affordable, short-term use of anti-TNF-alpha therapy, at the very early stages of RA. "Large-scale studies are under way to confirm these findings," Quinn reports.
Article: "Very Early Treatment With Infliximab in Addition to Methotrexate in Early, Poor-Prognosis Rheumatoid Arthritis Reduces Magnetic Resonance Imaging Evidence of Synovitis and Damage, With Sustained Benefit After Infliximab Withdrawal: Results From a Twelve-Month Randomized, Double-Blind, Placebo-Controlled Trial," Mark A. Quinn, Philip G. Conaghan, Philip J. O'Connor, Zunaid Karim, Adam Greenstein, Andrew Brown, Clare Brown, Alexander Fraser, Stephen Jarret, and Paul Emery, Arthritis & Rheumatism, January 2005; 52:1; pp. 27-35.
The above post is reprinted from materials provided by John Wiley & Sons, Inc.. Note: Content may be edited for style and length.
Cite This Page: